SUPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Supernus Pharmaceuticals Inc (SUPN) is not a strong buy for a beginner investor with a long-term focus at this time. While the company has shown positive revenue growth, its declining net income, EPS, and gross margin raise concerns about profitability. Additionally, the technical indicators and trading sentiment do not suggest a strong entry point currently. It is better to wait for clearer positive signals or improved financial performance before considering an investment.
The MACD is negatively expanding (-0.697), indicating bearish momentum. RSI is neutral at 23.391, and moving averages are converging, showing no clear trend. The stock is trading near its key support level (S1: 48.552), with resistance levels at R1: 54.885 and R2: 56.842. Overall, technical indicators suggest a weak or neutral trend.
Hedge funds have significantly increased their buying activity (+146.58% last quarter). Analysts have raised the price target to $65, citing resolution of supply constraints for Onapgo.
Insiders are heavily selling shares (+2510.70% last month), which could signal a lack of confidence in the company's near-term prospects. Additionally, no recent news or major catalysts have emerged to drive the stock higher.
In Q4 2025, revenue increased by 21.48% YoY to $211.57M, but net income dropped significantly to -$4.1M (-126.78% YoY), and EPS fell to -$0.07 (-125.93% YoY). Gross margin also declined slightly to 78.43% (-1.53% YoY), indicating deteriorating profitability.
Analysts maintain a Buy rating with a raised price target of $65 (up from $60), citing improved supply chain conditions. However, the lack of immediate catalysts and declining financial performance tempers enthusiasm.
